ASCO 2020 Header

Exclusive live coverage from the 2020 annual meeting of the American Society of Clinical Oncology (ASCO), brought to you by pharmaphorum and Syneos Health.

These exclusive highlights from the ASCO 2020 meeting, which takes place from Friday 29 May until Sunday 31 May, will cover sessions on cancer outcomes, immuno-oncology, the future of cancer treatment, market access in oncology and digital health in cancer.

Around 2,215 abstracts were accepted for presentation during this year’s programme, and more than 3,400 additional abstracts were accepted for online publication.

The annual cancer conference would usually be held in Chicago’s McCormick Place convention centre, but is this year being held virtually because of the COVID-19 pandemic and the travel restriction and lockdown measures that has required.

Other key topics that will be discussed at the 2020 ASCO conference include:

  • Overcoming limited access to cancer care
  • Targeted therapies for pancreatic, prostate, and paediatric cancers
  • Learning from cancer patients
  • Future directions in oncology
  • Personalised drug approaches

The live coverage of ASCO 2020 will also focus on key trial data in prostate cancer, lung cancer, gastrointestinal cancers and genitourinary cancers.

Highlights will likely include data from the phase 3 ADAURA study involving AstraZeneca’s Tagrisso (osimertinib).

There will also be data from an interim analysis of Pfizer/Merck KGaA’s Javelin Bladder 100, involving their immunotherapy Bavencio (avelumab).

Merck & Co’s Keytruda (pembrolizumab) helped to begin the immunotherapy revolution over the last few years, and the company will be presenting data from the KEYNOTE-177 study in MSI-high/MMR-deficient cancer. It represents the move towards a ‘tumour-agnostic’ approach that focuses on the genetic characteristics of a cancer rather than its location in the body.

There’s also data from Amgen’s Kyprolis (carfilzomib) for newly diagnosed multiple myeloma and Janssen has data from the phase 1b/2 CARTITUDE study, involving its CAR-T therapy JNJ-4528, which has shown promise in heavily pre-treated patient with multiple myeloma.

ASCO’s experts are also likely to address the changes to care that cancer patients receive as health systems quickly reconfigure to fight the pandemic.

Following the 29-31 May live coverage, additional analysis will be published on on, at the end of June, in the forthcoming Deep Dive: Oncology issue of its digital magazine.

Read exclusive coverage from:

Exclusive live coverage from Day 3 below:

Syneos Health ASCO 2020

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organisation. The Company, including a Contract Research Organisation (CRO) and Contract Commercial Organisation (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds, including 4,400 experts dedicated to oncology and haematology who collaborate with our customers to change the history of cancer treatments.  We embrace our customers’ boldest visions and bring experience, innovation and our passion to every oncology program we run.  Learn more at: